Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Eur J Radiol. 2021 May;138:109673. doi: 10.1016/j.ejrad.2021.109673. Epub 2021 Mar 20.
To evaluate the quality of radiomics studies on meningiomas, using a radiomics quality score (RQS), Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD), and the Image Biomarker Standardization Initiative (IBSI).
PubMed MEDLINE and Embase were searched to identify radiomics studies on meningiomas. Of 138 identified articles, 25 relevant original research articles were included. Studies were scored according to the RQS, TRIPOD guidelines, and items in IBSI.
Only four studies (16 %) performed external validation. The mean RQS was 5.6 out of 36 (15.4 %), and the basic adherence rate was 26.8 %. The adherence rate was low for stating biological correlation (4%), conducting calibration statistics (12 %), multiple segmentation (16 %), and stating potential clinical utility (16 %). None of the studies conducted a test‒retest or phantom study, stated a comparison to a 'gold standard', conducted prospective studies or cost-effectivity analysis, or opened code and data to the public, resulting in low RQS. The overall adherence rate for TRIPOD was 54.1 %, with low scores for reporting the title (4%), abstract (0%), blind assessment of the outcome (8%), and explaining the sample size (0%). According to IBSI items, only 6 (24 %), 6 (24 %), and 3 (12 %) studies performed N4 bias-field correction, isovoxel resampling, and grey-level discretization, respectively. No study performed skull stripping.
The quality of radiomics studies for meningioma is insufficient. Acknowledgement of RQS, TRIPOD, and IBSI reporting guidelines may improve the quality of meningioma radiomics studies and enable their clinical application.
使用放射组学质量评分（RQS）、用于个体预后或诊断的多变量预测模型的透明报告（TRIPOD）以及图像生物标志物标准化倡议（IBSI）来评估脑膜瘤的放射组学研究的质量。
在 PubMed MEDLINE 和 Embase 上进行搜索，以确定脑膜瘤的放射组学研究。在确定的 138 篇文章中，纳入了 25 篇相关的原始研究文章。根据 RQS、TRIPOD 指南和 IBSI 中的项目对研究进行评分。
仅有 4 项研究（16%）进行了外部验证。RQS 的平均得分为 36 分中的 5.6 分（15.4%），基本符合率为 26.8%。在说明生物学相关性（4%）、进行校准统计（12%）、多次分割（16%）和说明潜在临床效用（16%）方面，符合率较低。没有研究进行测试-再测试或体模研究，没有与“金标准”进行比较，没有进行前瞻性研究或成本效益分析，也没有公开代码和数据，导致 RQS 较低。TRIPOD 的总体符合率为 54.1%，在报告标题（4%）、摘要（0%）、结果评估的盲法（8%）和解释样本量（0%）方面得分较低。根据 IBSI 项目，只有 6 项（24%）、6 项（24%）和 3 项（12%）研究分别进行了 N4 偏置场校正、等体素重采样和灰度离散化。没有研究进行颅骨剥离。
脑膜瘤的放射组学研究质量不足。承认 RQS、TRIPOD 和 IBSI 报告指南可能会提高脑膜瘤放射组学研究的质量，并使其能够应用于临床。
